For optogenetic manipulation of membrane potentials neurons express opsins (light-sensing channels or pumps); applications of the appropriate wavelength of light then activates the opsin. Depending on the biophysical properties of the opsin, activation can result in an increase or decrease of membrane potential. Exchanging the physical light source (laser, arc lamp, or light-emitting diode) (Gradinaru et al., 2010; Kim et al., 2013) for a biological one (a luciferase emitting bioluminescence of the matching wavelength) expands optogenetics to non-invasive and circuit-wide applications. For such Bioluminescence-driven Optogenetics (BL-OG) the luciferase is fused to the opsin (luminopsin, LMO); application of the luciferin Abstract In Bioluminescent Optogenetics (BL-OG) a biological, rather than a physical, light source is used to activate light-sensing opsins, such as channelrhodopsins or pumps. This is commonly achieved by utilizing a luminopsin (LMO), a fusion protein of a lightemitting luciferase tethered to a light-sensing opsin. Light of the wavelength matching the activation peak of the opsin is emitted by the luciferase upon application of its small molecule luciferin, resulting in activation of the fused opsin and subsequent effects on membrane potential. Using optimized protocols for culturing, transforming, and testing primary neurons in multi electrode arrays, we systematically defined parameters under which changes in neuronal activity are specific to bioluminescent activation of opsins, rather than due to off-target effects of either the luciferin or its solvent on neurons directly, or on opsins directly. We further tested if there is a direct effect of bioluminescence on neurons. Critical for assuring specific BL-OG effects are testing the concentration and formulation of the luciferin against proper controls, including testing effects of vehicle on LMO expressing and of luciferin on non-LMO expressing targets. K E Y W O R D S coelenterazine, CTZ solvent, luminopsin, opsin, primary neuron Significance Bioluminescent Optogenetics, BL-OG, utilizes luciferases, luciferins, and opsins for neuronal manipulation. It is important to be aware of specific versus potential non-specific, off-target effects of individual components. Thus, we tested the effects of BL-OG components systematically in neuronal populations grown on multi electrode arrays (MEAs).
(the luciferase substrate) leads to an enzymatic reaction with emission of photons that in turn activate the opsin (Berglund, Birkner, Augustine, & Hochgeschwender, 2013; Berglund, Clissold, et al., 2016; Berglund, Tung et al., 2016; Park et al., 2017; Tung, Gutekunst, & Gross, 2015) .
In principle, any luciferase emitting sufficient light of the matching wavelength can be combined with an optogenetic element. Our LMOs fuse variants of Gaussia luciferase (GLuc, slGLuc, sbGLuc, GLucM23) to activating or silencing opsins (for example: ChR2, VChR1, Mac, iChloC, hGtARC2). The specific substrate for Gaussia luciferase is coelenterazine (CTZ). CTZ is the molecule for light energy storage in over 75% of luminous marine organisms (Haddock, Moline, & Case, 2010; Markova & Vysotski, 2015) and is the most abundant naturally occurring luciferin. It is the substrate for many common luciferases and photoproteins, including Renilla reniformis luciferase (Rluc) (Jeon et al., 2010; Zhao et al., 2004) and aequorin (Lark, Kitamoto, & Martin, 2016) . The bioluminescence reaction involving CTZ follows the conventional scheme: The luciferase catalyzes the oxidation of the CTZ molecule by O 2 , resulting in formation of oxyluciferin (coelenteramide) and CO 2 as by-products (Kaskova, Tsarkova, & Yampolsky, 2016) ; no other co-factors are required. A diverse range of in vitro analytical techniques are based on bioluminescence, such as immunological and gene expression assays. Bioluminescence can also be found in applications ranging from investigations of infectious disease to environmental studies (Badr & Tannous, 2011; Roda, Pasini, Mirasoli, Michelini, & Guardigli, 2004) . In vivo rodent cancer studies have extensively used CTZ for live bioluminescence imaging to monitor tumor growth or shrinkage. For all these applications, no toxic or adverse side effects have been reported. However, in none of these applications has CTZ been used to control neural activity.
In the presence of CTZ BL-OG effects are generally as expected (i.e., neurons are activated or silenced), regardless of whether the LMO-expressing neurons are in culture, in slices, or in behaving animals. However, different CTZ solvents, concentrations, and varying types of controls (vehicle, saline, or CTZ with non-LMO-expressing cells) are being used. As BL-OG utilizes combinations of luciferins, luciferases, and opsins in novel ways that have not been tested in the context of neuronal activation, we wanted to systematically explore specific and potential non-specific effects of BL-OG components.
Testing genetically encoded neuronal actuators, including LMOs, in vitro is usually carried out by patch clamp studies in primary neurons (Berglund, Clissold, et al., 2016; Berglund et al., 2013; Park et al., 2017; Tung et al., 2015) , requiring extensive equipment and expertise.
While there are membrane potential measurements that can only be carried out in single cells, assessment of neuronal populations can be highly informative as well. Multi-electrode arrays (MEAs) allow recording of the electrical activity of neuronal networks grown on multiple extracellular electrodes (Berdondini et al., 2009; Chiappalone, Bove, Vato, Tedesco, & Martinoia, 2006; Illes, Theiss, Hartung, Siebler, & Dihné, 2009; Novellino et al., 2011; Otto, Go, Fleischer, & Siebler, 2003; Quasthoff et al., 2015; Schock et al., 2012) . The advantages of this technology are its relative simplicity, compactness and ease of monitoring, as well as its potential for high throughput (Hales, Rolston, & Potter, 2010; Pine, 1980; Spira & Hai, 2013) . Thus, this study also serves as an example of the benefits of MEA experiments for initial screening of LMOs, as well as other neuronal manipulation tools, before using them in ex-vivo or in-vivo experiments.
| MATERIAL S AND ME THODS

| Coelenterazine (CTZ) and solvents
The luciferase substrate, coelenterazine (CTZ), was purchased from Nanolight Technology (Pinetop, AZ): Coelenterazine free base, the natural form of CTZ (Nanolight cat. no. 303); water soluble CTZ (Nanolight cat. no. 3031); CTZ Inject-A-Lume (Nanolight cat. no. 303INJ). The following solvents were used: NanoFuel (Nanolight cat. no. 399); acidified ethanol (0.06N HCl in ETOH); methanol (Fisher); 2-Hydroxypropyl-β-cyclodextrine (Sigma H5704, 20 mM in PBS/2% acidified ETOH); water (buffer only without CTZ, Nanolight cat. no. 3031C); Fuel-Inject (Nanolight cat. no. 303INJ).
| Neuron culture on MEAs
Primary neurons were collected from day 18 rat embryo cortex of both sexes obtained from pregnant Sprague Dawley females (RRID:RGD_5508397) from Harlan or BrainBits, LLC. Cortical neurons (4 × 10 4 cells/5 µl/well) were plated on the electrode area of 6-well or 1-well MEA dishes (60-6wellMEA200/30iR-Ti; 60MEA200/30iR-Ti; Multi Channel Systems, Germany) coated with PEI (0.1%) and laminin (50 µg/ml) in culture medium consisting of Neurobasal Medium (Invitrogen), B-27 supplement (Invitrogen), 2 mM Glutamax (Invitrogen) and 5% Fetal Calf Serum (FCS). The following day, the medium was replaced with culture medium without serum (NB-Plain medium). The neurons were left either un-transduced or transduced with adeno-associated virus (AAV2, serotype 9) on days in vitro 1 (DIV 1). The medium was replaced with NB-Plain medium every 3-4 days thereafter. All-trans retinal (R2500; Sigma-Aldrich, St. Louis, MO) was added to the culture medium to 1 µM final concentration before electrophysiological recordings. Neurons were used for recordings on DIV 12-19.
| Nucleofection
Nucleofection of E18 primary rat cortical neurons was carried out per manufacturer's instructions (Amaxa® Rat Neuron Nucleofector® Kit; LONZA) (Zeitelhofer, Vessey, Thomas, Kiebler, & Dahm, 2009; Zeitelhofer et al., 2007) . Briefly, 1 -5 × 10 6 primary neurons were collected and resuspended in 100 μl of Nucleofector® Solution at room temperature. The cell suspension was combined with 1-3 μg plasmid DNA and transferred to the nucleofection cuvette. The Nucleofector™ 2b Device (LONZA) was used for nucleofection with Nucleofector® Program "G-013".
Cells post-nucleofection were counted and plated in appropriate numbers in 1 well MEA dishes. The following day, the medium was replaced with NB-Plain medium. Expression from nucleofected plasmids was evident as early as 12 hr post-nucleofection. The cells were maintained and used for electrophysiological recordings as described below.
| MEA recordings
Consistently spiking neurons were used for recordings between DIV 12-19; only wells showing spontaneous electrophysiological activity were used. The stock solutions of all solvents were pre-diluted in NB-Plain medium to a final dilution of 1:50, achieved by adding 5 µl to 250 µl of MEA culture for 6-well MEAs, or by adding 10 µl to 500 µl of MEA culture for 1-well MEAs. Prior to recording, all reagents were pre-warmed to 37°C. MEAs were transferred from the CO 2 incubator to the heated MEA2100 head stage maintained at 37°C, and the cultures were allowed to equilibrate for 5-10 min. A micropipette was used to add reagents with the reagent drop gently touching the liquid surface. Recordings were carried out with a sample rate of 10,000 Hz.
After recording, the media in the wells was replaced with fresh NB-Plain media, and cultures were used for another round of recording the next day. MC Rack software was used for data acquisition. All 
| IVIS imaging
For measuring luminescence from neurons cultured on MEAs, reconstituted and diluted CTZ was added to the culture medium immediately before imaging to the final concentration indicated in the experiment. Luminescence was measured using an IVIS Lumina LT In Vivo Imaging System (PerkinElmer, Waltham, MA) with Living Image 4.5.2 software (RRID:SCR_014247). Images were displayed as a pseudo-color photon counted image. Regions of interest were defined using an automatic intensity contour procedure to identify bioluminescent signals with intensities significantly greater than background. The sum of the photon counts in these regions was then calculated.
| Statistics
Data are presented as mean ± SEM. All statistical tests were performed in SPSS (IBM). Neural cell cultures were monitored for variation in electrophysiological responses to solvent control across all cultures. This variation in spiking from solvent application was measured as ±20%. Conditions where changes in spikes fell within the 20% range from pre to post treatment were considered not different, and were not analyzed for statistical differences. Comparisons of spiking in neural cell cultures were done using a paired t-test to compare spikes before and after treatments. p < 0.05 was considered to be statistically significant.
| RE SULTS
| MEA for assessment of BL-OG effects in neuronal populations
We used MEAs for assessment of specific effects, i.e., bioluminescence-induced activation of opsins, and potential non-specific off-target effects of BL-OG ( Figure 1 ). We cultured embryonic rat cortical neurons on 1-well (64 electrodes) or 6-well (6 × 9 electrodes)
MEAs. Neurons were transformed to express constructs either by transduction with AAV2/9 vectors a day after plating (Figure 1a 
| Effects of solvents ± CTZ
CTZ is chemically synthesized and soluble in organic solvents.
Recently, a water-soluble version of CTZ became available. In addition, proprietary solvents for specific in vitro and in vivo applications exist, such as NanoFuel and Inject-A-Lume respectively. To test for possible luciferase-independent, non-specific effects of some of the most commonly used CTZ preparations, we first recorded from un-transduced primary rat cortical neurons using MEAs. Cultures were treated with six different solvents alone (vehicle controls) or with CTZ dissolved in the respective solvents, in both cases at a final concentration of 100 µM (see Table 1 ). Solvents were assigned randomly to MEAs initially, with subsequent recordings arranged so that the same cultures were not exposed to the same treatments repeatedly. Thus, any solvent was tested in multiple independent cultures, and any culture was treated with multiple different solvents.
Recordings of electrical activity were continuous and spiking activity before and after addition of solutions was compared ( Figure 2) ; only data collected from spontaneously spiking neurons were used. The solvents with the least non-specific effects in either condition (without or with CTZ), were NanoFuel and the water soluble formulations. Overall, it appears that in un-transduced neurons the solvents by themselves, at least when applied at the concentrations shown, have an unwanted impact on the spiking activity of neurons.
| Effects of solvent concentrations ± CTZ
For two of the solvent formulations, NanoFuel and water soluble, we recorded the effect on spiking activity over a range of concentrations in un-transduced neurons. The solvent stocks without and with CTZ (see Table 1 ) were diluted in NB-Plain media to achieve final concentrations of CTZ between 50 and 1 µM, resulting in additional dilution of the solvents from two-fold to a hundred-fold relative to the concentrations used in Figure 1 . As can be seen in Figure 3 , NanoFuel produced a dose dependent effect (Twoway ANOVA Dose by CTZ, main effect for Dose: F(5,584) = 10.05, p = 3.05 × 10 −9 , N = 596), as well as a main effect for CTZ (F(5,584) = 6.61, p = 5.397 × 10 −6 , N = 596). This dose effect was differential between solvent and CTZ conditions (Interaction of CTZ with 
| Effects of CTZ on neurons expressing luciferase, opsin, or luminopsin
Using CTZ dissolved in NanoFuel at concentrations of 25 μM or lower provides strong bioluminescence as measured in an IVIS system without causing non-specific effects on neuronal spiking activity in un-transduced neurons as measured in MEAs. We next wanted to explore whether adding CTZ or vehicle has any effects on the activity of neurons expressing only an optogenetic element (without a luciferase), or expressing only a luciferase (without an opsin). Neurons expressing the activating opsin VChR1, or the inhibiting opsin hG-tARC2 (Govorunova, Sineshchekov, Janz, Liu, & Spudich, 2015) , or sbGLuc anchored to the cell membrane by fusion to the transmembrane sequence from the human CD4-2 sequence (Kim et al., 2011) were cultured on MEAs. As each construct carries a fluorescent reporter at its C-terminal, expression for each culture was verified by fluorescence microscopy. We first recorded from the opsin-express- ing neurons, and direct silencing as well as synaptic dis-inhibition of inhibitory opsin-expressing neurons. This will make it potentially difficult to tease apart specific from non-specific effects when using CTZ, so we pretreated cultures with kynurenic acid (1 mM), a glutamate receptor antagonist (Bekkers & Stevens, 1991) . Under these conditions, changes in spiking activity occurred as expected under blue light stimulation, with increases in firing rate for VChR1 expressing neurons (Figure 4a ; t(15) = −4.16, p = 0.0008, N = 16), and decreases in firing rate for hGtARC2 expressing neurons (Figure 4c ;
paired t-test: t(15) = 8.22, p = 6.155 × 10 −7 , N = 16). In contrast, addition of CTZ, or its vehicle, to these cultures resulted in responses below the solvent variation (Figure 4a,c) . Thus, CTZ at this concentration does not seem to have a direct effect on neurons themselves, nor an indirect effect on neuronal activity through opsins.
Next, we asked if the emission of biological light itself alters spiking activity in neurons. MEA cultures with neurons expressing a membrane-tethered sbGLuc, sbGLuc-CD4, were treated as described above. Here the stimulation by LED light served as a negative control, as these neurons did not express opsins. In this experiment, neither blue light nor CTZ produced a response beyond the solvent threshold ( Figure 4b) .
The above experiments demonstrate that CTZ at a working concentration of 25 µM or lower does not have a significant off-target effect in neurons cultured in MEAs. Utilizing the experimental design as described in the previous section, we exposed neurons of the same culture to blue LED light, to CTZ, and to vehicle, with neurons expressing the activating luminopsin LMO3 (sbGLuc-VChR1-EYFP; Figure 4d ) or the inhibiting luminopsin sbGLuc-hGtARC2-EYFP ( Figure 4e ). Exposure to LED as well as addition of CTZ to generate biological light resulted in the expected increase and decrease of spiking activity, respectively, while addition of vehicle did not F I G U R E 3 Effects of dilutions of solvents, alone or with CTZ, on untransduced primary neurons. Percent changes in firing rate with addition of solvent corresponding to increasing concentrations of CTZ of (a) NanoFuel alone, (b) NanoFuel with CTZ, (c) water soluble vehicle, and (d) water soluble CTZ. The shaded area represents the ±20% variation in electrophysiological responses to solvent control across all cultures. Both NanoFuel and water-soluble vehicle alone fell within this range, having non-significant effects on spiking activity. For the CTZ containing formulations, the highest dose of NanoFuel + CTZ (50 µM) showed significant effects on spiking activity (p < 0.05), while no significant differences were found between doses of water soluble CTZ change spiking activity significantly (Figure 4d 
| D ISCUSS I ON
Bioluminescence driven optogenetics requires oxidation of a luciferin by a luciferase, thereby delivering light to opsins for modulating F I G U R E 4 Effects of CTZ on neurons expressing luciferase, opsin, or luminopsin. Percent change in firing rate with exposure to blue LED light (Blue Light; blue bar), with addition of NanoFuel solvent (Solvent; pastel orange bar), and with addition of NanoFuel-dissolved CTZ to 5 μM final concentration (CTZ; orange bar). The shaded areas represent the expected variation in spiking, and effects within this range are considered non-significant. See text for statistical details. (a) Neurons expressing the excitatory opsin VChR1, but no luciferase, showed significant increases to LED light, but not to solvent or CTZ. (b) Neurons expressing the membrane-anchored (CD4-2) luciferase sbGLuc, but no opsin, showed no significant change in firing rate with neither LED, nor solvent or CTZ. (c) Neurons expressing the inhibitory opsin hGtARC2, but no luciferase, showed significant decreases to LED light, but not to solvent or CTZ. (d) In neurons expressing the excitatory luminopsin LMO3 (sbGLuc-VChR1) both blue light and CTZ induced significant increase in firing rate, while solvent alone had no effect. (e) In neurons expressing the inhibitory luminopsin sbGLuc-hGtARC2 blue light and CTZ induced significant decrease in firing rate, while solvent alone had no effect the activity of neurons expressing luciferase-opsin fusions, LMOs.
As a control for the specificity of the effect on neuronal spiking, changes in neuronal activity in the presence of the luciferin are compared to those with vehicle alone. As CTZ, the luciferin for most marine luciferases, can be dissolved in various organic compounds, we wanted to compare directly effects of different CTZ preparations. Furthermore, while the intended effect is a change in membrane potential of LMO expressing neurons, we wanted to test if there are any off-target effects of CTZ or its respective solvents on neurons directly, or on the opsin itself. Lastly, we evaluated if there are effects on neuronal activity through bioluminescent light emission itself.
Using a concentration often applied in in vivo bioluminescence imaging experiments six solvent formulations both with and without CTZ showed significant effects on neuronal spiking activity in untransduced primary neurons. We can speculate as to the mechanisms that are causing the observed effects for some of the solvents.
Methanol, for example, is known to cause retinal and optic nerve injury both in vivo and in vitro (Treichel, Henry, Skumatz, Eells, & Burke, 2003) . Methanol is sequentially metabolized to form formic acid, formaldehyde, and carbon dioxide by oxidative steps. Formate, the putative toxic metabolite of methanol inhibited cytochrome oxidase activity, a component of the electron transport chain involved in ATP synthesis, at higher concentrations (Wallace, Madeira, Cortopassi, & Jones, 1997) and showed neurotoxic effects on dissociated primary mouse neuronal cell cultures (Dorman, Bolon, & Morgan, 1993) . Also, there are reports about the receptor me- as β-methylated and β-sulfated cyclodextrins, has been reported for cortical neuronal cultures (Abulrob et al., 2005) . Nanofuel, watersoluble vehicle, and Inject-A-Lume are proprietary compositions.
Whether the observed electrophysiological artifacts of these as well as the above discussed solvents are caused by binding to a common or to different receptors on neurons, or by simply off-setting the ionic balance in the medium, would be conjecture. When we used lower concentrations for two of the CTZ solvents, Nanofuel and water-soluble solvent, their non-specific effects were reduced to acceptable levels, and this might also be the case for other solvents used in this study. Using these lower doses of Nanofuel and watersoluble solvent, with or without CTZ, in neurons expressing either an opsin alone or a luciferase alone resulted in minimal non-specific changes in firing frequency. In contrast, both excitatory (LMO3) and
inhibitory (sbGLuc-hGtARC2) LMO expressing cultures showed robust specific changes with CTZ, but not with vehicle.
In our studies, we used analysis of multi-unit spiking activity of . Specific effects should show significant differences between LMO expressing targets treated with CTZ versus LMO expressing targets treated with vehicle and versus non-LMO expressing targets with CTZ (a). Lack of significant differences in effects between the experimental and either one of the two control groups indicates non-specific effects, requiring tuning of experimental conditions (b, c). Lack of significant differences in effects between the experimental and the two control groups indicates that there is no effect (d) Dow, & Wilkinson, 1990; Gross, Williams, & Lucas, 1982; Pine, 1980; Regehr, Pine, Cohan, Mischke, & Tank, 1989; Thomas, Springer, Loeb, Berwald-Netter, & Okun, 1972) , the approach has become increasingly sophisticated for studying neuronal communication, information encoding, propagation, and processing (Obien, Deligkaris, Bullmann, Bakkum, & Frey, 2015; Spira & Hai, 2013) . Other applications for MEAs include pharmacological testing and neurotoxicity screening (Alloisio, Nobile, & Novellino, 2015; Jenkinson et al., 2017) . For any application, it is important to realize the limitations of this approach.
First, neurons that do not fire action potentials during a recording (Bekkers & Stevens, 1991) , to such cultures blocked the paradoxical effects, suggesting that the effects in the absence of kynurenic acid were due to post-synaptic network effects. We are currently refining the use of specific blocking agents in MEA recordings. Overall, MEA recordings from cultured cortical neurons for assessing effects of LMOs on membrane potential proved to be efficient in terms of time and resources.
Our main motivation for these studies was to insure that in experiments using LMOs the changes in neuronal activity observed upon application of luciferase substrate are the result of bioluminescent activation of opsins. This implies that potential off-target effects needed to be ruled out in appropriate control experiments. We carried out these studies in MEA cultures, allowing for semi-high throughput analysis and accordingly, a full set of control experiments, including testing for effects of luciferin as well as vehicle on neurons expressing LMOs, just the luciferase, just the opsin, and no transgene at all. It is not realistic to test every permutation for every experiment. Given our results, this is also not necessary, as we found, for example, no evidence of effects of luciferin or vehicle on opsins directly, nor of bioluminescence itself on neuronal activity. Based on the results presented here, the most pertinent control experiments will be to evaluate the effects of vehicle in the LMO expressing group, and of CTZ in the non-LMO expressing group. This would be the case for experiments with cultured neurons, brain slices, and animals. Depending Similarly, testing behaviors when stimulating cortical circuits or thalamic circuits each require their matching controls. None of these recommendations pertain specifically to bioluminescence driven optogenetics, but are general considerations for good experimental design. As such, they apply to luminopsins, DREADDs, and standard optogenetics alike.
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